Analyzing Akoya Biosciences (NASDAQ:AKYA) and Singular Genomics Systems (NASDAQ:OMIC)
Analyzing Akoya Biosciences (NASDAQ:AKYA) and Singular Genomics Systems (NASDAQ:OMIC)
Singular Genomics Systems (NASDAQ:OMIC – Get Rating) and Akoya Biosciences (NASDAQ:AKYA – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.
纳斯达克：OMIC-GET评级公司和赤谷生物科学公司(纳斯达克：AKYA-GET评级)都是小盘医疗公司，但哪只股票更好？我们将根据这两家公司的收益、股息、盈利能力、分析师建议、机构所有权、风险和估值等方面的实力进行对比。
Profitability
盈利能力
This table compares Singular Genomics Systems and Akoya Biosciences' net margins, return on equity and return on assets.
此表比较了Single Genonomy Systems和Akoya Biosciences的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Singular Genomics Systems | N/A | -29.16% | -25.41% |
| Akoya Biosciences | -99.49% | -70.53% | -37.60% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 奇异基因组学系统 | 不适用 | -29.16% | -25.41% |
| Akoya生物科学 | -99.49% | -70.53% | -37.60% |
Earnings and Valuation
收益和估值
This table compares Singular Genomics Systems and Akoya Biosciences' revenue, earnings per share and valuation.
这张表格比较了单基因组系统公司和Akoya生物科学公司的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Singular Genomics Systems | N/A | N/A | -$98.77 million | ($1.25) | -1.69 |
| Akoya Biosciences | $54.92 million | 7.45 | -$42.94 million | ($1.85) | -5.83 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 奇异基因组学系统 | 不适用 | 不适用 | -9,877万元 | ($1.25) | -1.69 |
| Akoya生物科学 | 5492万美元 | 7.45 | -4,294万元 | ($1.85) | -5.83 |
Analyst Recommendations
分析师建议
This is a summary of recent ratings and target prices for Singular Genomics Systems and Akoya Biosciences, as reported by MarketBeat.com.
据MarketBeat.com报道，这是Single Genome Systems和Akoya Biosciences最近的评级和目标价格摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Singular Genomics Systems | 1 | 2 | 0 | 0 | 1.67 |
| Akoya Biosciences | 0 | 0 | 5 | 0 | 3.00 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 奇异基因组学系统 | 1 | 2 | 0 | 0 | 1.67 |
| Akoya生物科学 | 0 | 0 | 5 | 0 | 3.00 |
Singular Genomics Systems currently has a consensus target price of $3.50, suggesting a potential upside of 65.88%. Akoya Biosciences has a consensus target price of $17.80, suggesting a potential upside of 65.12%. Given Singular Genomics Systems' higher possible upside, analysts plainly believe Singular Genomics Systems is more favorable than Akoya Biosciences.
奇异基因组公司目前的共识目标价为3.50美元，这意味着潜在的上行空间为65.88%。Akoya Biosciences的共识目标价为17.80美元，暗示潜在上涨65.12%。考虑到单一基因组系统公司更有可能的上行空间，分析师们显然认为，单一基因组系统公司比Akoya Biosciences更有利。
Insider & Institutional Ownership
内部人与机构所有权
56.3% of Singular Genomics Systems shares are owned by institutional investors. Comparatively, 34.6% of Akoya Biosciences shares are owned by institutional investors. 22.6% of Singular Genomics Systems shares are owned by company insiders. Comparatively, 9.2% of Akoya Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
奇异基因系统公司56.3%的股份由机构投资者持有。相比之下，Akoya Biosciences 34.6%的股份由机构投资者持有。奇异基因系统公司22.6%的股份由公司内部人士持有。相比之下，Akoya Biosciences 9.2%的股份由公司内部人士持有。强大的机构持股表明，大型基金管理公司、捐赠基金和对冲基金相信，一家公司有望实现长期增长。
Volatility and Risk
波动性和风险
Singular Genomics Systems has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Akoya Biosciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.
奇异基因系统公司的贝塔系数为0.84，这表明其股价的波动性比标准普尔500指数低16%。相比之下，Akoya Biosciences的贝塔系数为0.97，这表明其股价的波动性比标准普尔500指数低3%。
Summary
摘要
Singular Genomics Systems beats Akoya Biosciences on 8 of the 13 factors compared between the two stocks.
奇异基因组学系统公司在两只股票之间的13个因素中有8个超过了Akoya Biosciences。
About Singular Genomics Systems
关于奇异基因组学系统
(Get Rating)
(获取评级)
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
单一基因组系统公司是一家生命科学技术公司，开发下一代测序和多组学技术，为研究人员和临床医生制造产品，促进科学和医学的发展。该公司制造G4仪器，一种台式下一代测序仪，用于产生基因测序结果，以及相关的消耗品套装菜单。它还提供PX集成解决方案，将单细胞分析、空间分析、基因组学和蛋白质组学结合到一个集成仪器中，提供多功能的多组学解决方案。该公司与安捷伦技术公司、Dovetail基因组公司、利克森公司、New England Biolab公司、QIAGEN公司、罗氏公司、Twist Bioscience公司和钟表制造商基因组公司建立了合作伙伴关系，以在G4上验证他们的图书馆准备试剂盒，并与麻省理工学院和哈佛大学的博德研究所和哈佛大学合作，将G4连接到Terra平台，这是一个数据平台。Single Genome Systems，Inc.成立于2016年，总部位于加利福尼亚州拉荷亚。
About Akoya Biosciences
关于Akoya Bioscions
(Get Rating)
(获取评级)
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Akoya Biosciences，Inc.是一家生命科学技术公司，提供空间生物学解决方案，专注于改变北美、亚太地区、欧洲、中东和非洲的发现和临床研究。该公司提供PhenoCycler仪器和PhenoImager平台，PhenoCycler仪器是一个紧凑的台式流体系统，与配套显微镜集成以实现图像采集自动化；PhenoImager平台使研究人员能够利用自动化和高通量的工作流程可视化、分析、量化新鲜冰冻或FFPE组织切片中的原位细胞和组织微阵列。它还提供PhenoCycler和PhenoImager试剂；以及生物制药服务。此外，该公司还提供基于云的平台Proxima，用于存储、分析和共享空间数据；INFORM组织，用于准确可视化和量化组织切片中的生物标记物的自动化图像分析软件包；Phenoptr，提供合并和分析INFO软件创建的输出表的功能；以及PhenoptrReports，一种在直观的前端图形用户界面中基于Phenoptr输出生成可共享报告和可视化的软件。该公司成立于2015年，总部位于马萨诸塞州马尔伯勒。
Receive News & Ratings for Singular Genomics Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Singular Genomics Systems and related companies with MarketBeat.com's FREE daily email newsletter.
《奇异基因组学系统日报》获得新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻的每日简明摘要和分析师对Single Genome Systems及相关公司的评级。